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Objectives: In cystic ﬁbrosis (CF), discrepancies have been reported between
antibiotic susceptibility for Pseudomonas aeruginosa (Pa) and clinical efﬁcacy.
Given the “hands-on” time needed for the agar diffusion method that is used for
Pa antibiotic susceptibility testing (AST), stringent cost constraints prompted us
to reconsider our politics of systematically assaying all Pa isolates obtained from
sputum samples of CF patients.
Methods: In a cohort of adult CF patients, we have reduced the frequency to
which AST was performed on Pa isolates to not more than once every six months:
when AST was performed less than six months before, only the presence and
quantiﬁcation of Pa was mentioned to the clinician. This change was monitored
over a 1-year period. All isolates (with or without AST) were kept frozen and the
clinician had the possibility to selectively request for unscheduled AST if needed.
Results: 1578 CF sputum samples from 444 CF patients were sent to the labo-
ratory over one year (3.5 sample/patient). 844 samples (54%) were positive with
>103 CFU/mL Pa. AST of Pa was done for 386 samples (46% of Pa-positive
samples). 250 patients (56%) had at least one sample positive with Pa. The average
annual number of AST was 1.5 per Pa-positive patient, 95% of them having at least
one AST over one year. The clinicians requested extra AST in only one case over
the analysed time period.
Conclusion: Reducing by approximately one half the frequency of AST for Pa
isolates did not lead clinicians to ask for additional AST, and the costs related to Pa
AST were signiﬁcantly reduced. These results might be of interest for reevaluating
the frequency of Pa AST in adult CF patients.
61 Baseline data from a prospective 5-year registry study to monitor
susceptibility to aztreonam of Pseudomonas aeruginosa (PA)
isolates from patients with cystic ﬁbrosis (CF) in the United States
E. DiMango1, L. Saiman1, M. McKevitt2, S.A. Lewis2, M. Bresnik3, B. Marshall4,
J.L. Burns5. 1Columbia University Medical Center, New York, United States;
2Gilead Sciences, Seattle, United States; 3Gilead Sciences, Foster City, United
States; 4Cystic Fibrosis Foundation, Bethesda, United States; 5University of
Washington, Seattle, United States
Objectives: A Phase 4 observational study is prospectively monitoring PA suscep-
tibility patterns and clinical data in a subset of subjects in the CF Foundation (CFF)
Registry over a 5-yr period after introduction of Cayston® (AZLI).
Methods: Subjects 6 yrs old, FEV1 25% to 90% predicted and documented 2
PA-positive respiratory tract cultures were recruited from CFF-accredited centers.
Sputum samples are collected at baseline and once yearly for 5 yrs and processed
at a central reference laboratory. Study evaluations include PA susceptibility to
aztreonam and other antibiotics; relationship between number of AZLI treatment
courses and PA resistance to aztreonam (parenteral susceptibility breakpoint: MIC
>8mg/mL); and decreases in PA susceptibility to aztreonam or other antibiotics
associated with changes in CFF Registry database clinical evaluations.
Results: 510 subjects enrolled (August to November, 2011). Mean age: 26 yrs
(range 6 to 71); Subjects 18 yrs: 377 (73.9%). Mean FEV1 %predicted at
enrollment: 60.4 (range 17–104). 278 subjects (54.5%) received 1 AZLI course
in the preceding 1 year; 130 (25.5%) received 5 AZLI courses. Baseline sputum
pathogens: PA (77%), S. aureus (MSSA 24%/MRSA 26%), S. maltophilia (11%),
Achromobacter spp. (6%), Burkholderia spp. (2%), Aspergillus spp. (18%). Aztre-
onam MIC50/MIC90 for all PA isolates (612 PA strains/391 PA-positive samples)
were 4 and 128 mg/mL; 38% of subjects had a PA isolate with an aztreonam
MIC >8mg/mL.
Conclusions: This observational cohort study provides opportunities to document
changes in PA antibiotic resistance patterns and possible associations with clinical
outcomes over a 5 yr period.
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Objectives: Minimum bioﬁlm eradication concentration (MBEC) assay with peg-
lid microtiter plate has been well developed for bioﬁlm susceptibility test. But the
method includes long-term assay of 4−6 days and bioﬁlm formation difﬁculties in
some mucoid P. aeruginosa strains. In this study a novel bioﬁlm antimicrobial
susceptibility assay is proposed as a development for guidance of antibiotic
administration in cystic ﬁbrosis (CF) patients.
Methods: P. aeruginosa PAO1 (non-mucoid), PDO300 (mucoid) and NH57388A
(mucoid clinical strain from CF lung) were imbedded in alginate/agarose beads (50–
100mm in diameter). 0.1ml of 5×106cfu/ml beads was added in 96-wells microtiter
plate treated by 0.1ml antibiotics for 4−8h in a minimal medium. Live/Dead-Kit was
used to quickly detect the MBEC of antibiotics on the beads bioﬁlm by ﬂuorescent
microscopy. After sonication, 0.1ml samples were diluted and cultured on plates
or added in LB media overnight to conﬁrm the MBEC data from ﬂuorescent
microscopy. As a control, the peg-lid MBEC assay was performed in parallel. All
experiments were repeated two times.
Results: MBEC of azithromycin, aztreonam, ceftazidime, ciproﬂoxacin, colistin,
imipenem, meropenem, tobramycin was 4–1024 mg/ml by peg-lid microtiter plate
method. Similar MBEC results were found in alginate/agarose beads bioﬁlm with
8–1024mg/ml. The results attained by Live/Dead-Kit agreed with the CFU-results.
Time spent on peg-lid bioﬁlm susceptibility assay was 5 days, but only 12−24h for
alginate/agarose bioﬁlm susceptibility assay.
Conclusion: Alginate/agarose bioﬁlm antimicrobial susceptibility assay is a promis-
ing candidate method for clinical application.
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Despite increased knowledge and research over the past decades, bioﬁlm infections
are still difﬁcult to manage. We suggest considering bioﬁlms as independent
compartments with particular pharmacokinetics.
To examine our thesis the pharmacokinetics was related to the pharmacodynamics
of tobramycin in an alginate-embedded bioﬁlm model.
Seaweed alginate beads with Pseudomonas aeruginosa were prepared. The beads
were placed in LB medium and grown at 37ºC. At day 1, 3, 5, or 7 bacteriology
was determined for beads treated with tobramycin for 30 minutes in physiological
treatment concentrations and non-treated beads. The beads were homogenized,
serially diluted and the number of CFUs determined after overnight incubation.
Tobramycin concentrations in the solution of homogenized beads were measured
(Architect). Finally, beads were studied using a confocal laser scanning microscope
(Zeiss Zen 2010). Live cells were visualized by Syto9 and dead cells by propidium
iodidee staining.
Tobramycin concentrations were stable throughout our experiment (range
30−42mg/l, MIC = 1.0mg/l). CFU per bead were lower in the tobramycin treated
as compared to the non treated group (p< 0.016). The quantitative and the relative
bacterial killing were reduced from day 1 to day 7. Through the study period
increasing sizes as well as more superﬁcial positioning of the micro-colonies within
the beads was demonstrated.
The present study, resembling physiological pharmacokinetics of tobramycin
demonstrates a good distribution of tobramycin in an in vitro bioﬁlm model.
However, the effect was reduced as bioﬁlms matured. The present model may add
knowledge to optimize treatment of bioﬁlm infections.
